Clinical Trial Update: Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating safety, tolerability, efficacy, and dose-response of GSK2831781 in ulcerative colitis has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• GSK2831781

Snippet

Sponsor: GlaxoSmithKline | Conditions: Colitis, Ulcerative | Phase 2 | Status: TERMINATED | Results posted: 2022-04-27